MoreBack to News Headlines


Experimental Alzheimer's drug could slow cognitive decline in patients, early results suggest
CNN
Eli Lilly and Company's experimental intravenous drug donanemab could slow the cognitive decline of patients with Alzheimer's disease, according to early clinical trial results, published in The New England Journal of Medicine on Saturday.
The study included 257 patients with early symptomatic Alzheimer's disease; 131 received donanemab, while 126 received a placebo. The researchers found donanemab slowed the decline of cognition and daily function in Alzheimer's patients by 32% after 76 weeks, compared to those who received a placebo. Taken over 18 months, that 32% slowing of decline could be noticeably impactful for Alzheimer's patients, noted Maria Carrillo, chief science officer at the Alzheimer's Association, who was not involved in the study.More Related News

Ukraine’s military commander in charge of the country’s drone warfare program urged the US and NATO countries alike on Wednesday to learn from Kyiv’s use of the technology on the battlefield so in the future there are not “hard questions from your children [about] when [their] father will come back.”